pasteur
clot
factor
viii
fviii
concentr
introduc
germani
brand
name
fviii
c
hs
behr
origin
formul
contain
albumin
later
replac
saccharos
glycin
regist
germani
beriat
p
initi
formul
fviii
concentr
iuml
specif
activ
approxim
iumg
protein
subsequ
advanc
product
process
enabl
solvent
volum
reduc
led
launch
beriat
p
fviii
concentr
iuml
mean
specif
activ
approxim
iumg
protein
manufactur
develop
includ
chang
diamet
chromatographi
column
increas
fviii
yield
improv
purif
process
optim
lyophil
programm
beriat
p
iu
fviii
beriat
p
regist
treatment
prophylaxi
hereditari
haemophilia
use
treatment
acquir
haemophilia
fraction
plasma
protein
beriat
p
consid
excel
safeti
profil
report
viru
transmiss
germani
caus
product
year
rigor
select
process
donor
minim
potenti
risk
transmiss
infecti
diseas
human
immunodefici
viru
hiv
caus
acquir
immunodefici
syndrom
aid
viral
hepat
particularli
common
hepat
hav
hepat
b
hbv
hepat
c
hcv
virus
furthermor
rigor
select
also
effect
potenti
pathogen
diseas
variant
creutzfeldtjakob
diseas
vcjd
viru
inactiv
procedur
pasteur
reduc
risk
viru
transmiss
effect
reduceelimin
potenti
viru
load
wide
rang
virus
eg
hiv
hbv
hcv
bovin
diarrhoea
viru
includ
newli
identifi
pathogen
eg
west
nile
viru
sever
acut
respiratori
syndrom
influenza
virus
singl
blood
donat
sourc
plasma
sourc
plasma
plasma
gener
plasmapheresi
select
donor
product
beriat
p
screen
antihiv
type
antibodi
antihepat
c
antibodi
hepat
b
surfac
antigen
use
serolog
assay
addit
donat
pool
minipool
test
relev
viru
deoxyribonucl
acid
ribonucl
acid
rna
hcv
hbv
hav
hiv
parvoviru
use
polymeras
chain
reaction
pcr
event
posit
test
result
reactiv
defin
threshold
respect
singl
donat
identifi
discard
donor
temporarili
perman
exclud
donat
test
serolog
assay
genet
assay
take
place
level
manufactur
pool
estim
haemophilia
patient
develop
fviii
neutral
antibodi
occurr
antibodiesinhibitor
consid
one
seriou
complic
treatment
haemophilia
patient
determin
incid
fviii
inhibitor
identifi
marker
viru
transmiss
patient
popul
receiv
beriat
p
undertook
retrospect
analysi
patient
receiv
treatment
period
identifi
haemophilia
patient
receiv
treatment
beriat
p
csl
behr
gmbh
marburg
germani
centr
point
januari
decemb
investig
relat
viru
safeti
safeti
paramet
perform
patient
annual
routin
review
substitut
therapi
bleed
episod
document
patient
diari
patient
rate
treatment
efficaci
excel
good
suffici
suffici
requir
addit
treatment
analysi
diari
perform
standard
manner
everi
month
centr
depend
patient
clot
factor
consumpt
patient
also
question
regard
treatment
dose
use
followup
treatment
requir
subject
overal
treatment
effect
excel
good
suffici
suffici
patient
receiv
home
therapi
treat
centr
document
addit
laboratori
investig
undertaken
patient
underw
complet
medic
examin
gener
bleed
histori
record
retrospect
analys
data
standard
routin
medic
document
ethic
approv
studi
requir
patient
provid
inform
consent
data
analys
studi
immunoglobulin
assess
via
nephelometri
immunoglobulin
g
normal
rang
g
mgdl
mgdl
mgdl
addit
lymphocyt
differenti
includ
ratio
evalu
differenti
lymphocyt
investig
determin
total
number
lymphocyt
normal
rang
total
lymphocyt
normal
rang
total
b
lymphocyt
normal
rang
helper
cell
normal
rang
suppressor
cell
normal
rang
ratio
normal
rang
activ
total
cell
normal
rang
total
natur
killer
cell
normal
rang
case
surgeri
aim
fviii
level
around
time
surgeri
follow
fviii
trough
level
day
end
first
week
requir
use
iukg
bodi
weight
bw
clot
factor
concentr
day
oper
line
treatment
guidelin
achiev
fviii
level
follow
assess
fviii
plasma
level
minut
administr
depend
time
surgeri
anoth
iu
administ
hour
postop
fviii
plasma
level
hour
anoth
bw
administ
first
second
sometim
third
postop
day
approxim
iu
calcul
accord
patient
bodi
weight
administ
everi
hour
plasma
fviii
level
check
daili
patient
also
receiv
oral
tranexam
acid
administ
heparin
thromboprophylaxi
period
evalu
patient
mean
age
year
rang
year
one
patient
year
old
one
year
old
remaind
adult
haemophilia
receiv
beriat
p
ondemand
treatment
patient
surgeri
patient
prophylaxi
includ
intermitt
secondari
prophylaxi
patient
surgeri
excess
bleed
overal
patient
sever
haemophilia
two
moder
haemophilia
two
mild
haemophilia
three
subclin
haemophilia
one
patient
previous
untreat
pup
remain
patient
previous
treat
ptp
cryoprecipit
owe
treatment
practic
former
eastern
part
germani
time
n
exposur
day
ed
repres
patientyear
mean
yearspati
consumpt
iu
beriat
p
total
nine
patient
receiv
treatment
entir
studi
period
hivposit
individu
sampl
patient
pcrposit
hcv
result
prior
use
cryoprecipit
demograph
data
mutat
type
summar
tabl
patient
identifi
origin
sampl
still
use
beriat
p
replac
therapi
remain
patient
either
die
patient
switch
recombin
fviii
product
patient
consumpt
beriat
p
vari
significantli
patient
tabl
rang
treatment
patient
mild
haemophilia
almost
iu
year
treatment
patient
sever
haemophilia
underw
two
surgic
procedur
within
total
patient
group
consumpt
beriat
p
year
assess
iu
analys
per
year
per
patient
mean
consumpt
iu
seen
patient
sever
haemophilia
tabl
averag
dose
per
patient
per
year
per
kg
patient
sever
patient
iu
iu
respect
sixteen
haemophilia
patient
underw
surgic
procedur
includ
total
joint
replac
eight
orthopaed
procedur
one
cholecystectomi
tabl
total
iu
beriat
p
administ
iu
administ
total
knee
replac
surgeri
one
case
total
hip
replac
also
perform
mean
consumpt
standard
deviat
per
oper
per
patient
median
consumpt
per
oper
per
patient
iukg
home
treatment
bleed
failur
efficaci
beriat
p
rate
excel
good
patient
nearli
bleed
event
respond
first
administr
beriat
p
almost
bleed
patient
remain
bleed
requir
two
administr
throughout
entir
observ
period
seroconvers
viru
paramet
investig
includ
hiv
hav
hbv
hcv
advers
event
includ
allerg
reaction
record
administr
beriat
p
studi
report
thrombosi
inhibitor
identifi
patient
time
studi
one
patient
sever
haemophilia
experienc
less
ed
find
signific
abnorm
immunolog
paramet
investig
includ
ratio
result
support
previou
observ
virusinactiv
human
plasmaderiv
coagul
factor
concentr
excel
safeti
profil
although
patient
receiv
beriat
p
observ
studi
million
iu
product
administ
without
transmiss
virus
develop
inhibitor
ptp
pup
kreuz
colleagu
previous
publish
result
viru
safeti
studi
pasteur
clot
factor
concentr
report
transmiss
hav
hbv
hcv
case
seroconvers
contrast
patient
haemophilia
von
willebrand
diseas
treat
humanplasmaderiv
clot
product
includ
specif
step
inactiv
remov
virus
posit
reaction
antibodi
detect
patient
longitudin
studi
patient
haemophilia
b
von
willebrand
diseas
factor
x
defici
receiv
pasteur
concentr
seroconvers
hiv
observ
followup
period
year
anoth
landmark
studi
demonstr
safeti
pasteur
fviii
concentr
regard
hepat
patient
haemophilia
previou
infus
data
studi
group
confirm
safeti
virusinactiv
plasmaderiv
coagul
factor
concentr
minim
risk
viral
transmiss
human
plasmaderiv
clot
product
undergo
sever
product
step
effect
reduc
prion
load
log
increas
safeti
also
keep
theoret
risk
transmit
prion
associ
diseas
vcjd
small
possibl
one
suspect
case
vcjd
transmiss
report
haemophilia
patient
without
clinic
sign
vcjd
whose
treatment
includ
one
batch
fviii
product
manufactur
plasma
donor
develop
symptom
vcjd
month
donat
plasma
uk
result
us
food
drug
administr
plasmaderiv
fviii
risk
assess
model
suggest
risk
potenti
plasmaderiv
fviii
product
transmit
vcjd
infect
highli
uncertain
appear
like
extrem
small
turn
inhibitor
risk
haemophilia
patient
public
rousselrobert
et
al
describ
preval
inhibitor
sever
ptp
bdomaindelet
recombin
product
contrast
lusher
et
al
report
one
fviii
inhibitor
ptp
use
bdomaindelet
recombin
product
followup
studi
inhibitor
rate
ptp
remain
unchang
inhibitor
rate
pup
inhibitor
pup
yoshioka
et
al
report
incid
hightitr
fviii
inhibitor
pup
receiv
recombin
babi
hamster
kidney
cellderiv
fviii
prepar
kreuz
et
al
report
incid
pup
minim
treat
patient
receiv
fulllength
sucroseformul
version
recombin
fviii
studi
report
low
inhibitor
frequenc
ptp
one
patient
ptp
investig
recombin
fviii
product
prepar
use
plasmaalbuminfre
method
pup
data
product
report
region
inhibitor
incid
pup
predecessor
product
inhibitor
gener
also
observ
differ
plasmaderiv
fviii
product
incid
inhibitor
found
patient
sever
haemophilia
receiv
crude
intermediatepur
concentr
compar
inhibitor
data
patient
sever
haemophilia
receiv
recombin
fviii
product
limit
two
patient
treat
followup
studi
period
differ
immunogen
plasmaderiv
recombin
fviii
product
could
confirm
followup
studi
number
patient
present
ed
receiv
plasmaderiv
product
compar
receiv
recombin
product
interestingli
review
wight
paisley
reveal
incid
inhibitor
lower
haemophilia
patient
use
singl
plasmaderiv
fviii
product
use
singl
recombin
fviii
product
question
whether
inhibitor
risk
best
investig
ptp
pup
controversi
late
intern
societi
thrombosi
haemostasi
isth
subcommitte
propos
ptp
exposur
day
form
appropri
studi
popul
purpos
howev
higher
inhibitor
rate
seem
occur
pup
may
suggest
greater
sensit
earlier
detect
inhibitori
potenti
popul
sever
risk
factor
inhibitor
gener
identifi
unrel
type
product
use
highrisk
fviii
gene
defect
posit
famili
histori
inhibitor
ethnic
polymorph
immuneregul
gene
age
first
exposur
fviii
intens
treatment
base
result
obtain
canal
studi
odd
ratio
univari
analys
differ
factor
posit
famili
histori
inhibitor
high
risk
gene
mutat
type
intens
treatment
day
first
treatment
age
first
exposur
b
month
surgeri
reason
first
treatment
risk
factor
taken
account
inhibitor
studi
potenti
studi
bia
exclud
summari
period
year
use
beriat
p
shown
excel
efficaci
safeti
profil
product
induc
inhibitor
associ
thrombosi
surgeri
beriat
p
becam
avail
germani
thank
excel
efficaci
safeti
profil
still
use
today
